文献速递银屑病与炎症性皮肤病

银屑病IL-23抑制剂抗药抗体系统综述

Anti-drug antibodies of IL-23 inhibitors for psoriasis: a systematic review.
PubMed 文献 · J Eur Acad Dermatol Venereol · 2022-03-18

本系统综述检索PubMed、Cochrane和Embase数据库共318篇文献,最终纳入19篇,评估银屑病患者使用IL-23抑制剂后抗药抗体的发生率、对临床结局的影响及不良事件关联。古塞奇尤单抗抗药抗体发生率4.1-14.7%,瑞莎珠单抗141-31%,替拉珠单抗6.51-18%;仅抗药抗体存在无证据显示疗效降低,但高滴度或中和抗体可能降低临床应答。

要点

  • 古塞奇尤单抗抗药抗体发生率4.1-14.7%,瑞莎珠单抗141-31%,替拉珠单抗6.51-18%。
  • 仅抗药抗体存在无证据显示银屑病治疗疗效降低。
  • 高抗药抗体滴度或中和抗体存在时部分研究报告临床应答降低。

核心结论

  • 仅检测抗药抗体存在似乎不能预测该患者群体的治疗应答,检测中和抗体或抗药抗体滴度值可能更有价值,但需进一步研究以显示明确相关性。

研究设计与样本

  • 系统检索PubMed、Cochrane和Embase数据库共获得318篇文献并人工审查,最终19篇符合纳入标准。

主要发现

  • 古塞奇尤单抗抗药抗体发生率为4.1-14.7%,瑞莎珠单抗为141-31%,替拉珠单抗为6.51-18%。
  • 中和抗体发生率:古塞奇尤单抗为01-0.6%,瑞莎珠单抗为21-16%,替拉珠单抗为2.5至3.2%。
  • 仅抗药抗体存在无证据显示银屑病治疗疗效降低,但部分研究发现高抗药抗体滴度或中和抗体存在时临床应答降低。
  • 少数研究报告古塞奇尤单抗和瑞莎珠单抗抗药抗体阳性的患者注射部位反应发生率更高。
  • 似乎没有其他与IL-23抑制剂抗药抗体相关的不良事件。

关键数值与推荐

  • 古塞奇尤单抗抗药抗体发生率4.1-14.7%,中和抗体发生率01-0.6%。
  • 瑞莎珠单抗抗药抗体发生率141-31%,中和抗体发生率21-16%。
  • 替拉珠单抗抗药抗体发生率6.51-18%,中和抗体发生率2.5至3.2%。

临床怎么用

  • 作者认为仅检测抗药抗体存在似乎不能预测治疗应答,检测中和抗体或抗药抗体滴度值可能更有价值,但需进一步研究以显示明确相关性。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Anti-drug antibodies (ADAs) can form with certain biological medications, but their clinical significance is not fully understood. ADA formation in psoriasis patients treated with IL-23 inhibitors was evaluated, looking at the incidence of ADAs, impact on clinical outcomes and association with adverse events. A systematic search of PubMed, Cochrane and Embase databases yielded 318 articles, which were manually reviewed. A total of 19 articles met the eligibility criteria. The incidence of ADAs with the IL-23 inhibitors was as follows: 4.1-14.7% with guselkumab, 141-31% with risankizumab and 6.51-18% with tildrakizumab. The incidence of neutralizing antibodies ranged from 01-0.6% with guselkumab, 21-16% with risankizumab and 2.5 to 3.2% with tildrakizumab. There was no evidence of reduced efficacy of psoriasis treatment with ADA presence alone. However, some studies found a reduction in clinical response with high ADA titres or with the presence of neutralizing antibodies. A few studies reported that patients with ADAs to guselkumab and risankizumab had a higher incidence of injection site reactions (ISRs). There do not appear to be other adverse events associated with ADAs with IL-23 inhibitors. Testing for presence of ADAs alone in this patient group does not appear to be predictive of treatment response. Clinically, it may be more productive to test for neutralizing antibodies or ADA titre values, although further investigation is required to show a definitive correlation.

来源:J Eur Acad Dermatol Venereol,查看原文。版权归原作者所有。

引用

  1. Norden A, Moon JY, Javadi SS, et al. Anti-drug antibodies of IL-23 inhibitors for psoriasis: a systematic review. J Eur Acad Dermatol Venereol. 2022. PMID: 35246887. doi:10.1111/jdv.18042

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。